Abstracts Archive - Page 1614 of 2425 - ACR Meeting Abstracts

Abstract Number: 2955 • 2016 ACR/ARHP Annual Meeting
Biologic Therapy in Severe Peripheral Ulcerative Keratitis (PUK). Multicenter Study of 27 Patients
Lucia C. Domínguez-Casas¹, Vanesa Calvo-Río¹, Olga Maiz², Ana Blanco³, Emma Beltran⁴, L. Martinez-Costa⁵, Maria Concepcion Alvarez de Buergo⁶, Esteban Rubio-Romero⁷, David Diaz-Valle⁸, R. López-González⁹, Angel M. Garcia-Aparicio¹⁰, Antonio Juan Mas¹¹, Natalia Palmou-Fontana¹, Miguel Angel Gonzalez-Gay¹ and Ricardo Blanco¹², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Hospital Universitario Donostia, Donostia, Spain, ³Hospital Universitario Donostia, San Sebastian, Spain, ⁴Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ⁵Hospital Dr. Peset., Valencia, Spain, ⁶Hosp. Rio Carrion, Palencia, Spain, ⁷Rheumatology Department,, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁸Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain, ⁹Rheumatology, Complejo Hospitalario de Zamora, Zamora, Spain, ¹⁰Rheumatology, Hospital Virgen de la Salud, Toledo, Spain, ¹¹Rheumatology, Hospital Son Llàtzer., Palma de Mallorca., Spain, ¹²Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Peripheral Ulcerative Keratitis (PUK) is a severe inflammation of the outer portions of the cornea that may be associated with systemic conditions. The…
Abstract Number: 2956 • 2016 ACR/ARHP Annual Meeting
Optimization of Thiopurines with a Xanthine Oxidase Inhibitor in Patients with Autoimmune Systemic Diseases
Mériem Belhocine¹, Aurélie Chapdelaine¹, Maxime Doré², Yves Troyanov³ and Anne-Marie Mansour¹, ¹medicine, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, ²Pharmacy, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, ³Rheumatology, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada
Background/Purpose: Thiopurines are a mainstay for the treatment of autoimmune diseases. However, in inflammatory bowel diseases (IBD), 14-18 % of patients manifest a skewed metabolism…
Abstract Number: 2957 • 2016 ACR/ARHP Annual Meeting
Primary Central Nervous System Vasculitis Associated with Lymphomas
Carlo Salvarani¹, Robert D. Brown Jr.², Teresa J. H. Christianson³, Caterina Giannini⁴, John Huston III⁵, Stephen M Ansell⁶ and Gene G. Hunder⁷, ¹Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ²Department of Neurology, Mayo Clinic, Rochester, MN, ³Division of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN, ⁴Division of Anatomic Pathology, Mayo Clinic, Rochester, MN, ⁵Department of Radiology, Mayo Clinic, Rochester, MN, ⁶Mayo Clinic, Rochester, MN, ⁷Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: The occurrence of lymphoma, especially Hodgkin’s lymphoma (HL), in patients with primary central nervous system vasculitis (PCNSV) has been reported but is considered uncommon. The…
Abstract Number: 2958 • 2016 ACR/ARHP Annual Meeting
Hypocomplementemic Urticarial Vasculitis (HUV) Syndrome in Two Geographically Defined Populations of Sweden
Christopher Sjöwall¹, Thomas Mandl² and Aladdin Mohammad^3,4, ¹Linköping University, Department of Clinical and Experimental Medicine Rheumatology/AIR, Linköping, Sweden, ²Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Rheumatology, Malmö, Sweden, Malmö, Sweden, ³Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Rheumatology, Lund, Sweden, Lund, Sweden, ⁴Addenbrooke’s Hospital, Vasculitis and Lupus Clinic, Cambridge, UK, Cambridge, United Kingdom
Background/Purpose: Since first described by McDuffie et al. in 1973, hypocomplementemic urticarial vasculitis (HUV) syndrome has been recognized as a specific autoimmune disorder involving at…
Abstract Number: 2959 • 2016 ACR/ARHP Annual Meeting
Baseline Endothelial Dysfunction Might Predict Immunosuppressive Need in Young, Male Behcet’s Patients with Early Disease: A Prospective Follow-up
Fatma Alibaz-Oner¹, Emrah Karatay², Belgin Aldag¹, I.Nuri Akpınar², Tulin Ergun³ and Haner Direskeneli⁴, ¹Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ²Radiology, Marmara University, School of Medicine, Istanbul, Turkey, ³Marmara University, School of Medicine, Dermatology, Istanbul, Turkey, ⁴Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Major organ involvement, especially in young males, is one of the main causes of mortality and morbidity in Behcet’s Disease (BD). However, the prognosis…
Abstract Number: 2960 • 2016 ACR/ARHP Annual Meeting
Increased Post-Thrombotic Syndrome Is Unassociated with Anticoagulant Use in Vascular Behcet’s Disease
Fatma Alibaz-Oner¹, Belgin Aldag¹, Mustafa Aldag², Ali Ugur Unal¹, Aydan Mutiş³, Tayfur Toptas⁴, Tulin Ergun⁵ and Haner Direskeneli⁶, ¹Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ²Dr.Siyami Ersek Cardiovascular Surgery Hospital,, Istanbul, Turkey, ³Marmara University, School of Medicine, Rheumatology, ISTANBUL, Turkey, ⁴Marmara University, School of Medicine, Hematology, Istanbul, Turkey, ⁵Marmara University, School of Medicine, Dermatology, Istanbul, Turkey, ⁶Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Deep venous thrombosis (DVT) is the most common form of vascular involvement in Behcet’s disease (BD). Chronic post-thrombotic syndrome (PTS) develops frequently in patients…
Abstract Number: 2961 • 2016 ACR/ARHP Annual Meeting
Antiphospoholipid Antibodies in Adult IgA Vasculitis: Aps/PT Antibodies As a Potential Marker of Renal Involvement?
Alojzija Hocevar, Jaka Ostrovrsnik, Polona Žigon, Saša Čučnik, Ziga Rotar and Matija Tomšič, Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Increased prevalence of IgA aCL and anti-PS/PT antibodies has been described in adult IgAV, making them potential markers of disease activity1. The aim of our…
Abstract Number: 2962 • 2016 ACR/ARHP Annual Meeting
Expression Profile of Chemokines Is Skewed to Th17/Th22 Recruitment in Circulation of Patients with Behcet’s Disease
Hidekata Yasuoka and Tsutomu Takeuchi, Keio University School of Medcine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan
Background/Purpose: Behcet’s disease (BD) is an inflammatory disease characterized by ocular, mucosal and skin lesions. However, the pathogenesis of BD is still unknown. Characteristics of…
Abstract Number: 2963 • 2016 ACR/ARHP Annual Meeting
BehçEt’s Disease in Children: Eastern Mediterranean Experience
Hafize Emine Sonmez¹, Ezgi Deniz Batu¹, Betul Sozeri², Yonatan Butbul Aviel³, Yelda Bilginer⁴ and Seza Ozen⁵, ¹Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Pediatric Rheumatology, Erciyes University Faculty of Medicine, Kayseri, Turkey, ³Pediatric Rheumatology, Rambam Medical Center, Haifa, Israel, ⁴Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ⁵Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Behçet’s disease (BD) is a variable vessel vasculitis which is more common in adults. The most widely used diagnostic criteria for adult onset disease…
Abstract Number: 2964 • 2016 ACR/ARHP Annual Meeting
Thromboangiitis Obliterans (Buerger’s disease) : An Observational Study of 174 Patients
Alexandre LE JONCOUR¹, Simon Soudet², Hélène Maillard², Fabien Koskas³, Philippe Cluzel⁴, Eric Hachulla⁵, Pierre-Yves Hatron⁵, Patrice Cacoub¹, Marc Lambert² and David Saadoun¹, ¹Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et d’Immunologie clinique, DHU i2B, Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, ²Department of internal medecine, Hôpital Claude Huriez, CHRU Lille, France, Lille, France, ³Department of vascular surgery, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁴Department of cardiovascular imagery, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié Salpétrière, 83 Boulevard de l'Hôpital, 75013, Paris, France., Paris, France, ⁵CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France
Background/Purpose: Buerger’s disease or thromboangiitis obliterans (TAO) is a nonatherosclerotic segmental inflammatory disease of small- and medium-sized arteries of the distal extremities. This disease mainly…
Abstract Number: 2965 • 2016 ACR/ARHP Annual Meeting
Late-Onset Relapse in Patients with Systemic Vasculitis
Rennie L. Rhee¹, Natasha Dehghan², Antoine G. Sreih³, David Cuthbertson⁴, Simon Carette⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Curry L. Koening⁸, Jeffrey Krischer⁹, Carol A. Langford¹⁰, Carol A. McAlear¹¹, Paul A. Monach¹², Larry W. Moreland¹³, Christian Pagnoux¹⁴, Philip Seo¹⁵, Ulrich Specks¹⁶, Steven R. Ytterberg¹⁷ and Peter A. Merkel¹⁸, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, The University of Pennsylvania, Philadelphia, PA, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, Cleveland Clinic, Cleveland, OH, ⁷McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁸Rheumatology, University of Utah, Salt Lake City, UT, ⁹University of South Florida, Tampa, FL, ¹⁰Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁵Medicine, Johns Hopkins University, Baltimore, MD, ¹⁶Mayo Clinic, Rochester, MN, ¹⁷Rheumatology, Mayo Clinic, Rochester, MN, ¹⁸Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA
Background/Purpose: Little is known about the incidence of late-onset relapse in systemic vasculitis. This study examined the incidence of relapse < 2 years and ≥ 2…
Abstract Number: 2966 • 2016 ACR/ARHP Annual Meeting
Assessment of Damage in Behcet’s Disease: Do We Need a Specific Damage Index?
Ali Ugur Unal¹, Hale Gulcin Yildirim², Ceylan Cikikci², Gulsen Ozen³, Nevsun Inanc³, Pamir Atagunduz³, Tulin Ergun⁴ and Haner Direskeneli⁵, ¹Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ²Marmara University Faculty of Medicine, Istanbul, Turkey, ³Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁴Marmara University, School of Medicine, Dermatology, Istanbul, Turkey, ⁵Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Behcet’s Disease (BD) is a systemic vasculitis characterized by involvement of vessels of any size and type. In the course systemic vasculitis, it is…
Abstract Number: 2967 • 2016 ACR/ARHP Annual Meeting
Identifying Core Domains for BehçEt’s Syndrome Trials: An International Physician and Patient Delphi Exercise
Alexa Meara¹, Yesim Ozguler², Alfred Mahr³, Haner Direskeneli⁴, Ahmet Gul⁵, Yusuf Yazici⁶, Hasan Yazici², Peter A. Merkel⁷ and Gulen Hatemi², ¹Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Hospital Saint-Louis, Paris, France, ⁴Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁵Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁶Rheumatology, New York University Medical Center, La Jolla, CA, ⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: An unmet need for reliable, validated, and widely accepted outcome measures for trials in BehetÕs syndrome (BS) was identified through: i) a systematic review;…
Abstract Number: 2968 • 2016 ACR/ARHP Annual Meeting
Efficacy of Anti-TNF Alpha in Severe and Refractory Cardiovascular Involvement of Behcet’s Disease: A Multicenter Observational Study of 18 Patients
Anne-Claire Desbois¹, Olga Addimanda², Marc Lambert³, Eric Hachulla³, F. Ackermann⁴, Benjamin subran⁵, Arnaud Hot⁶, Francois Maurier⁷, christelle mausservey⁸, Fanny Bernard⁹, tristan mirault¹⁰, Fleur Cohen¹¹, Laurent Perard¹², Gaelle Leroux¹³, nicolas champtiaux¹⁴, Patrice Cacoub¹⁵ and David Saadoun¹⁶, ¹Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, Paris, France, ²Rheumatology Unit, Istituto Ortopedico Rizzoli, Bologna, Italy, ³CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ⁴internal medicine, Hopital Foch, Suresnes, France, ⁵hopital foch, suresnes, France, ⁶Internal Medicine, Hopital Edouard Herriot, Lyon, France, ⁷Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁸CH Chalon sur saone, Chalon sur saone, France, ⁹CHU Marseille, marseille, France, ¹⁰HEGP, paris, France, ¹¹Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ¹²Hôpital Edouard Herriot, Lyon, France, ¹³Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ¹⁴Pitié SAlpétrière, paris, France, ¹⁵Department of Internal Medicine, Pitié-Salpêtrière Hospital, Paris, France, ¹⁶Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France
Background/Purpose: In Behçet's disease (BD), vascular complications affect more than 30% patients. Cardiovascular involvement is the main cause of death, especially for pulmonary or aortic…
Abstract Number: 2969 • 2016 ACR/ARHP Annual Meeting
10 Year Retrospective Analysis of 276 Cases of Histopathologically Confirmed Leukocytoclastic Vasculitis
Shazdeh Butt¹ and Thomas Olenginski², ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Department of Rheumatology, Geisinger Medical Center, Danville, PA
Background/Purpose: We identified leukocytoclastic vasculitis (LCV) patients seen over 10 years at our institution. Aims included 1) define cause; 2) record lab, imaging, and ancillary…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].